Theriva Biologics (TOVX) is scheduled to present additional subgroup analyses from the VIRAGE study today at the American Association for Cancer Research (AACR) Annual Meeting 2026, which evaluates VCN-01 in combination with gemcitabine and nab-paclitaxel in newly diagnosed metastatic pancreatic cancer patients.
The data, to be shared in a poster presentation by Dr. Manuel Hidalgo of NYU Langone Health, highlight improved outcomes across multiple patient groups, including those with liver metastases.
VCN-01, also known as zabilugene almadenorepvec, is a systemically administered oncolytic adenovirus designed to selectively replicate within tumor cells and degrade the tumor stroma- a barrier that often limits the effectiveness of cancer therapies. By breaking down this barrier, VCN-01 enhances chemotherapy access, increases tumor immunogenicity, and exposes cancer cells to the patient's immune system.
Earlier clinical observations showed that patients receiving VCN-01 plus chemotherapy experienced longer response durations and improved survival compared to chemotherapy alone. Building on these findings, Theriva has aligned with both the FDA and EMA on plans for a pivotal Phase 3 trial to evaluate multiple dosing regimens of VCN-01 in the first-line metastatic regimens of VCN-01 in first-line metastatic PDAC. The company is also preparing a smaller study to test whether extended dosing schedules could further improve patient outcomes.
Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of pancreatic cancers and is often diagnosed at advanced stages, leaving limited treatment options. With only a fraction of cases eligible for surgical resection, novel therapies like VCN-01 represent a critical area of research.
Theriva's upcoming presentation at AACR 2026 reflects its continued commitment to advancing treatments in areas of high unmet need, with VCN-01 positioned as a promising candidate to reshape outcomes for patients facing one of the most aggressive forms of cancer.
TOVX has traded between $0.16 and $1.50 over the past year. The stock closed Friday's trading (April 17, 2026) at $0.25, up 1.94%. During the overnight trading session, the stock rose further to $0.46, up 79.08%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.